{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T18:10:23Z","timestamp":1762193423955,"version":"build-2065373602"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic human immunodeficiency virus (HIV) infection continues to pose a major global health challenge, with an estimated 39.9\u00a0M cases and 1.3\u00a0M new infections per year. Up to 75%, of people with HIV (PWH) are currently being treated with antiretroviral therapy. The development of effective treatments for HIV requires a detailed understanding of the virus-host interaction. Often, mathematical models are used to inform this understanding as well as to characterize therapeutic response. This work aims to develop a single and fully identifiable population semi-mechanistic pharmacokinetic\/pharmacodynamic (popPKPD) model integrating data (drug levels, CD4\u2009+\u2009T cells and viral RNA) of five different antiretroviral (ARV) drugs administered in monotherapy: lenacapavir, bictegravir, tenofovir alafenamide, emtricitabine and elvitegravir. Data were obtained from six phase 1 clinical studies and model development was performed using NONMEM 7.5.1. The viral dynamics were best described by expanding the \u201cbasic\u201d viral dynamics model with two more populations of infected cells: chronically and latently infected. Obtained death rates values of infected cells &amp; virus were consistent with literature values. Population baseline HIV-RNA was estimated to be 43,460 copies\/mL, with an IIV of 141%, the estimated baseline concentrations of CD4\u2009+\u2009cells varied largely across the different cell types in the model: 410, 20, 7 and 7 cells\/mL for uninfected, infected, chronic and latently infected cells, respectively. The popPKPD model was able to capture key aspects of viral dynamics, drug behaviour, and treatment response. The models developed will serve as a useful tool for further development and optimization of these HIV therapies, especially when evaluating multiple ARVs to be administered in a novel combination setting.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1208\/s12248-025-01136-4","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T16:36:59Z","timestamp":1760373419000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated Population Pharmacokinetic-pharmacodynamic Modeling of HIV Virus-host Infection Dynamics in Patients Undergoing Antiretroviral Monotherapy"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0514-5470","authenticated-orcid":false,"given":"Alberto","family":"Vegas Rodriguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2699-9265","authenticated-orcid":false,"given":"Nieves","family":"Velez de Mendiz\u00e1bal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3076-0003","authenticated-orcid":false,"given":"Yanan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-3423","authenticated-orcid":false,"given":"Jason T.","family":"Hindman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0567-4445","authenticated-orcid":false,"given":"Ramesh","family":"Palaparthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3700-8658","authenticated-orcid":false,"given":"I\u00f1aki F.","family":"Troc\u00f3niz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5462-3110","authenticated-orcid":false,"given":"Ana","family":"Ru\u00edz-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-7087","authenticated-orcid":false,"given":"Justin S.","family":"Feigelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"1136_CR1","unstructured":"Global HIV Programme [Internet]. [cited 2023 Dec 3]. Available from: https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/strategic-information\/hiv-data-and-statistics"},{"key":"1136_CR2","unstructured":"HIV Basics | HIV\/AIDS | CDC [Internet]. [cited 2023 Dec 3]. Available from: https:\/\/www.cdc.gov\/hiv\/basics\/index.html"},{"issue":"6205","key":"1136_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.1256739","volume":"346","author":"NR Faria","year":"2014","unstructured":"Faria NR, Rambaut A, Suchard MA, Baele G, Bedford T, Ward MJ, et al. The early spread and epidemic ignition of HIV-1 in human populations. Science. 2014;346(6205):56\u201361.","journal-title":"Science"},{"key":"1136_CR4","unstructured":"WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach [Internet]. 2016 [cited 2023 Dec 3];(2016):XXXii. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK374294\/"},{"issue":"1","key":"1136_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.35","volume":"1","author":"SG Deeks","year":"2015","unstructured":"Deeks SG, Overbaugh J, Phillips A, Buchbinder S. HIV infection. Nat Rev Dis Primers. 2015;1(1):15035.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"1136_CR6","first-page":"4","volume":"1","author":"M Balasubramaniam","year":"2019","unstructured":"Balasubramaniam M, Pandhare J, Dash C. Immune control of HIV. JoLS, Journal of Life Sciences. 2019;1(1):4\u201337.","journal-title":"JoLS, Journal of Life Sciences"},{"key":"1136_CR7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/oso\/9780198504184.003.0003","volume-title":"Virus Dynamics: Mathematical Principles of Immunology and Virology","author":"MA Nowak","year":"2000","unstructured":"Nowak MA, May RM. Virus Dynamics: Mathematical Principles of Immunology and Virology. Oxford: Oxford University Press; 2000. p. 16\u201343."},{"issue":"1","key":"1136_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1006\/bulm.2001.0266","volume":"64","author":"D Callaway","year":"2002","unstructured":"Callaway D. HIV-1 infection and low steady state viral loads. Bull Math Biol. 2002;64(1):29\u201364.","journal-title":"Bull Math Biol"},{"issue":"4","key":"1136_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10928-012-9257-1","volume":"39","author":"J Fang","year":"2012","unstructured":"Fang J, Jadhav PR. From in vitro EC 50 to in vivo dose-response for antiretrovirals using an HIV disease model. Part II: Application to drug development. J Pharmacokinet Pharmacodyn. 2012;39(4):369\u201381.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"1136_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10928-012-9255-3","volume":"39","author":"J Fang","year":"2012","unstructured":"Fang J, Jadhav PR. From in vitro EC 50 to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework. J Pharmacokinet Pharmacodyn. 2012;39(4):357\u201368.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"1136_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mbs.2005.12.006","volume":"200","author":"MS Ciupe","year":"2006","unstructured":"Ciupe MS, Bivort BL, Bortz DM, Nelson PW. Estimating kinetic parameters from HIV primary infection data through the eyes of three different mathematical models. Math Biosci. 2006;200(1):1\u201327.","journal-title":"Math Biosci"},{"issue":"3","key":"1136_CR12","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s11538-007-9279-9","volume":"70","author":"H Wu","year":"2008","unstructured":"Wu H, Zhu H, Miao H, Perelson AS. Parameter identifiability and estimation of HIV\/AIDS dynamic models. Bull Math Biol. 2008;70(3):785\u201399.","journal-title":"Bull Math Biol"},{"issue":"4","key":"1136_CR13","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jtbi.2009.04.010","volume":"259","author":"D Burg","year":"2009","unstructured":"Burg D, Rong L, Neumann AU, Dahari H. Mathematical modeling of viral kinetics under immune control during primary HIV-1 infection. J Theor Biol. 2009;259(4):751\u20139.","journal-title":"J Theor Biol"},{"issue":"6","key":"1136_CR14","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/clpt.2010.35","volume":"87","author":"E Snoeck","year":"2010","unstructured":"Snoeck E, Chanu P, Lavielle M, Jacqmin P, Jonsson EN, Jorga K, et al. A comprehensive hepatitis c viral kinetic model explaining cure. Clin Pharmacol Ther. 2010;87(6):706\u201313.","journal-title":"Clin Pharmacol Ther"},{"key":"1136_CR15","unstructured":"Daar E MCCG et al. Dose-response Relationship of Subcutaneous Long-Acting HIV Capsid Inhibitor GS-6207. Vol. 77(4), Conference on Retroviruses and Opportunistic Infections (CROI). . Boston, MA, 2020.: J Antimicrob Chemother.; 2022. p. 989\u201395."},{"issue":"1","key":"1136_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/QAI.0000000000001306","volume":"75","author":"JE Gallant","year":"2017","unstructured":"Gallant JE, Thompson M, DeJesus E, Voskuhl GW, Wei X, Zhang H, et al. Antiviral activity, safety, and pharmacokinetics of Bictegravir as 10-day monotherapy in HIV-1\u2013infected adults. JAIDS J Acquir Immune Defic Syndr. 2017;75(1):61\u20136.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"1","key":"1136_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.qai.0000233308.82860.2f","volume":"43","author":"E DeJesus","year":"2006","unstructured":"DeJesus E, Berger D, Markowitz M, Cohen C, Hawkins T, Ruane P, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. JAIDS J Acquir Immune Defic Syndr. 2006;43(1):1\u20135.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"1136_CR18","unstructured":"Markowitz M ZARP et al. GS-7340 Demonstrates Greater Declines in HIV-1 RNA than Tenofovir Disoproxil Fumarate During 14 Days of Monotherapy in HIV-1 Infected Subjects [Oral Presentaton \/ Paper 152LB]. Paper presented at: 18th Conference on Retroviruses and Opportunistic Infections (CROI). ; Boston, MA: February 27 - March 2; 2011."},{"issue":"4","key":"1136_CR19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","volume":"63","author":"PJ Ruane","year":"2013","unstructured":"Ruane PJ, DeJesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, et al. Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1\u2013positive adults. JAIDS J Acquir Immune Defic Syndr. 2013;63(4):449\u201355.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"4","key":"1136_CR20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/jac\/48.4.507","volume":"48","author":"FS Rousseau","year":"2001","unstructured":"Rousseau FS. Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J Antimicrob Chemother. 2001;48(4):507\u201313.","journal-title":"J Antimicrob Chemother"},{"key":"1136_CR21","unstructured":"Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ. NONMEM 7.5.1 Users guides. USA ICON Dev Solut, Hanover, MD (2018) 1989."},{"issue":"5","key":"1136_CR22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481\u2013504.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1136_CR23","unstructured":"Beal SL and SLB and BA and BRJ. NONMEM users guides. NONMEM Project Group, University of California, San Francisco. 1992;"},{"issue":"2","key":"1136_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J"},{"issue":"2","key":"1136_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/psp4.12161","volume":"6","author":"THT Nguyen","year":"2017","unstructured":"Nguyen THT, Mouksassi MS, Holford N, Al-Huniti N, Freedman I, Hooker AC, et al. Model evaluation of continuous data pharmacometric models: Metrics and graphics. CPT Pharmacometrics Syst Pharmacol. 2017;6(2):87\u2013109.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"1136_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0025-5564(93)90043-A","volume":"114","author":"AS Perelson","year":"1993","unstructured":"Perelson AS, Kirschner DE, De Boer R. Dynamics of HIV Infection of CD4+ T cells. Math Biosci. 1993;114(1):81\u2013125.","journal-title":"Math Biosci"},{"key":"1136_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1000533","author":"L Rong","year":"2009","unstructured":"Rong L, Perelson AS. Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol. 2009. https:\/\/doi.org\/10.1371\/journal.pcbi.1000533.","journal-title":"PLoS Comput Biol"},{"issue":"6510","key":"1136_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/373123a0","volume":"373","author":"DD Ho","year":"1995","unstructured":"Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373(6510):123\u20136.","journal-title":"Nature"},{"issue":"5255","key":"1136_CR29","first-page":"1582","volume":"271","author":"AS Perelson","year":"1996","unstructured":"Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time. Sci (1979). 1996;271(5255):1582\u20136.","journal-title":"Sci (1979)"},{"issue":"1","key":"1136_CR30","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1086\/315640","volume":"182","author":"JM Orenstein","year":"2000","unstructured":"Orenstein JM. In vivo cytolysis and fusion of human immunodeficiency virus type 1\u2013infected lymphocytes in lymphoid tissue. J Infect Dis. 2000;182(1):338\u201342.","journal-title":"J Infect Dis"},{"issue":"21","key":"1136_CR31","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJM199905273402101","volume":"340","author":"L Zhang","year":"1999","unstructured":"Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340(21):1605\u201313.","journal-title":"N Engl J Med"},{"issue":"6","key":"1136_CR32","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nm880","volume":"9","author":"JD Siliciano","year":"2003","unstructured":"Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9(6):727\u20138.","journal-title":"Nat Med"},{"issue":"6629","key":"1136_CR33","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/387188a0","volume":"387","author":"AS Perelson","year":"1997","unstructured":"Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387(6629):188\u201391.","journal-title":"Nature"},{"issue":"11","key":"1136_CR34","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.molmed.2004.09.006","volume":"10","author":"K Lassen","year":"2004","unstructured":"Lassen K, Han Y, Zhou Y, Siliciano J, Siliciano RF. The multifactorial nature of HIV-1 latency. Trends Mol Med. 2004;10(11):525\u201331.","journal-title":"Trends Mol Med"},{"issue":"24","key":"1136_CR35","doi-asserted-by":"publisher","first-page":"13193","DOI":"10.1073\/pnas.94.24.13193","volume":"94","author":"TW Chun","year":"1997","unstructured":"Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JAM, Baseler M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997;94(24):13193\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1136_CR36","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/8394","volume":"5","author":"D Finzi","year":"1999","unstructured":"Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5(5):512\u20137.","journal-title":"Nat Med"},{"key":"1136_CR37","unstructured":"Baron K. mrgsolve: Simulate from ODE-Based Models. R package version 1.5.1. 2024."},{"issue":"8","key":"1136_CR38","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/QAD.0000000000000640","volume":"29","author":"G Marks","year":"2015","unstructured":"Marks G, Gardner LI, Rose CE, Zinski A, Moore RD, Holman S, et al. Time above 1500 copies: a viral load measure for assessing transmission risk of HIV-positive patients in care. AIDS. 2015;29(8):947\u201354.","journal-title":"AIDS"},{"issue":"1","key":"1136_CR39","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","volume":"101","author":"RJ Keizer","year":"2011","unstructured":"Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. Pira\u00f1a and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101(1):72\u20139.","journal-title":"Comput Methods Programs Biomed"},{"key":"1136_CR40","doi-asserted-by":"crossref","unstructured":"Hitchcock AM, Kufel WD, Dwyer KAM, Sidman EF. Lenacapavir: A novel injectable HIV-1 capsid inhibitor. Vol. 63, International Journal of Antimicrobial Agents. Elsevier B.V. 2024;63(1):107009","DOI":"10.1016\/j.ijantimicag.2023.107009"},{"key":"1136_CR41","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/82_2017_77","volume-title":"HIV-1 Latency","author":"AL Hill","year":"2018","unstructured":"Hill AL. Mathematical Models of HIV Latency. In: Silvestri G, Lichterfeld M, editors. HIV-1 Latency. Cham: Springer International Publishing; 2018. p. 131\u201356. https:\/\/doi.org\/10.1007\/82_2017_77."},{"issue":"6","key":"1136_CR42","first-page":"751","volume":"29","author":"S Hussen","year":"2019","unstructured":"Hussen S, Mama M, Mekonnen B, Yihune M, Shegaze M, Boti N, et al. Predictors of time to viral load suppression of adult PLWHIV on ART in Arba Minch General Hospital: a follow up study. Ethiop J Health Sci. 2019;29(6):751\u20138.","journal-title":"Ethiop J Health Sci"},{"key":"1136_CR43","unstructured":"\u00c2baut RT, Morlat P, \u00c2le H, Jacqmin-Gadda \u00c1, Neau D, Mercie P, et al. Clinical progression of HIV-1 infection according to the viral response during the \u00aerst year of antiretroviral treatment [Internet]. Available from: http:\/\/journals.lww.com\/aidsonline"},{"key":"1136_CR44","doi-asserted-by":"crossref","unstructured":"Homas T, Uinn CQ, Aria M, Awer JW, Elson N, Ewankambo S, et al. Volume 342 Number 13 \u00b7 921 VIRAL LOAD AND HETEROSEXUAL TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 VIRAL LOAD AND HETEROSEXUAL TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 Background and Methods We examined the influ. 2000.","DOI":"10.1056\/NEJM200003303421303"},{"key":"1136_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1003203","author":"N Beerenwinkel","year":"2013","unstructured":"Beerenwinkel N, Montazeri H, Schuhmacher H, Knupfer P, von Wyl V, Furrer H, et al. The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients. PLoS Comput Biol. 2013. https:\/\/doi.org\/10.1371\/journal.pcbi.1003203.","journal-title":"PLoS Comput Biol"},{"key":"1136_CR46","doi-asserted-by":"crossref","unstructured":"Nettles RE, Kieffer TL, Parsons T, Johnson J, Cofrancesco J, Gallant JE, et al. Marked Intraindividual Variability in Antiretroviral Concentrations May Limit the Utility of Therapeutic Drug Monitoring [Internet]. Available from: https:\/\/academic.oup.com\/cid\/article\/42\/8\/1189\/283194","DOI":"10.1086\/501458"},{"issue":"2","key":"1136_CR47","first-page":"37","volume":"3","author":"Carla M Kumbale","year":"2021","unstructured":"Kumbale Carla M, Voit Eberhard O. Toward Personalized Medicine for HIV\/AIDS. J AIDS HIV Treat. 2021Jul 15;3(2):37\u201341.","journal-title":"J AIDS HIV Treat"},{"issue":"4","key":"1136_CR48","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10928-012-9255-3","volume":"39","author":"J Fang","year":"2012","unstructured":"Fang J, Jadhav PR. From in vitro EC50 to in vivo dose\u2013response for antiretrovirals using an HIV disease model. Part I: a framework. J Pharmacokinet Pharmacodyn. 2012;39(4):357\u201368.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1136_CR49","unstructured":"Ferguson NM, deWolf F, Ghani AC, Fraser C, Donnelly CA, Reiss P, et al. Antigen-driven CD4 T cell and HIV-1 dynamics: Residual viral replication under highly active antiretroviral therapy [Internet]. Available from: www.pnas.org"},{"issue":"1","key":"1136_CR50","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0025-5564(93)90043-A","volume":"114","author":"AS Perelson","year":"1993","unstructured":"Perelson AS, Kirschner DE, De Boer R. Dynamics of HIV infection of CD4+ T cells. Math Biosci. 1993;114(1):81\u2013125.","journal-title":"Math Biosci"},{"key":"1136_CR51","doi-asserted-by":"publisher","unstructured":"Mendoza P, Jackson JR, Oliveira TY, Gaebler C, Ramos V, Caskey M, et al. Antigen-responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir. J Exp Med. 2020;217(7). https:\/\/doi.org\/10.1084\/jem.20200051.","DOI":"10.1084\/jem.20200051"},{"issue":"suppl_1","key":"1136_CR52","doi-asserted-by":"publisher","first-page":"i16","DOI":"10.1093\/bioinformatics\/btg1001","volume":"19","author":"N Beerenwinkel","year":"2003","unstructured":"Beerenwinkel N, Lengauer T, D\u00e4umer M, Kaiser R, Walter H, Korn K, et al. Methods for optimizing antiviral combination therapies. Bioinform. 2003;19(suppl_1):i16-25.","journal-title":"Bioinform"},{"key":"1136_CR53","first-page":"14","volume":"27","author":"X Pang","year":"2024","unstructured":"Pang X, Huang J, Tang K, Ma J, Fang N, Xie H, et al. Impact of HIV-1 genetic diversity on disease progression: a prospective cohort study in Guangxi. Front Cell Infect Microbiol. 2024;27:14.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"1136_CR54","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1758-2652-13-4","volume":"13","author":"PJ Easterbrook","year":"2010","unstructured":"Easterbrook PJ, Smith M, Mullen J, O\u2019Shea S, Chrystie I, de Ruiter A, et al. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc. 2010;13(1):4\u20134.","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"1136_CR55","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/cid\/civ963","volume":"62","author":"LM Hofstra","year":"2016","unstructured":"Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, et al. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe. Clin Infect Dis. 2016;62(5):655\u201363.","journal-title":"Clin Infect Dis"},{"key":"1136_CR56","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/COH.0b013e32833ed6f4","volume":"5","author":"DE Nixon","year":"2010","unstructured":"Nixon DE, Landay AL. Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS. 2010;5:498\u2013503.","journal-title":"Curr Opin HIV AIDS"},{"issue":"6","key":"1136_CR57","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/infdis\/jiz252","volume":"220","author":"S Kroeze","year":"2019","unstructured":"Kroeze S, Wit FW, Rossouw TM, Steel HC, Kityo CM, Siwale M, et al. Plasma biomarkers of human immunodeficiency virus-related systemic inflammation and immune activation in sub-Saharan Africa before and during suppressive antiretroviral therapy. J Infect Dis. 2019;220(6):1029\u201333.","journal-title":"J Infect Dis"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01136-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01136-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01136-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T17:59:01Z","timestamp":1762192741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01136-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":57,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["1136"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01136-4","relation":{},"ISSN":["1550-7416"],"issn-type":[{"type":"electronic","value":"1550-7416"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no competing interests for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"161"}}